{"version":1,"type":"story","url":"https://digestai.news/story/hansa-biopharma-adopts-cradles-ai-platform-for-autoimmune-disease-drug","json":"https://digestai.news/story/hansa-biopharma-adopts-cradles-ai-platform-for-autoimmune-disease-drug.json","markdown":"https://digestai.news/story/hansa-biopharma-adopts-cradles-ai-platform-for-autoimmune-disease-drug.md","slug":"hansa-biopharma-adopts-cradles-ai-platform-for-autoimmune-disease-drug","headline":"Hansa Biopharma adopts Cradle’s AI platform for autoimmune disease drug discovery","summary":"Hansa Biopharma deployed Cradle’s AI-driven protein design platform across its entire discovery pipeline on October 1, 2026. The partnership aims to accelerate development of novel immunomodulatory therapies for severe autoimmune diseases. Cradle’s platform integrates hit identification, optimization, and continuous learning from experimental data into a single workflow, which Hansa’s VP of Research, Sofia Järnum, called essential for next-generation protein engineering.\n\nCradle claims its platform delivers 2–12x speedups in drug development timelines, with customers reporting up to 18 months saved per clinical candidate. The companies announced the collaboration from offices in Lund, Sweden, and Amsterdam, Netherlands. Hansa’s lead product, imlifidase (Idefirix), is commercially available in Europe and under FDA review in the U.S., with a PDUFA date set for December 19, 2026.","keyPoints":["Hansa Biopharma uses Cradle’s AI platform for end-to-end protein design and optimization in autoimmune disease therapies","Cradle’s platform claims 2–12x speedups in drug development timelines, with 8/10 ratings for AI-engineered candidates","Hansa’s imlifidase faces FDA review for kidney transplant desensitization, with a PDUFA date of December 19, 2026"],"whyItMatters":"This partnership highlights how AI-driven protein engineering is reshaping drug discovery, potentially cutting timelines and costs for biologics targeting rare autoimmune diseases.","category":{"slug":"research","name":"Research","url":"https://digestai.news/category/research"},"entities":{"companies":["Hansa Biopharma AB","Cradle","Genethon","Sarepta Therapeutics","Charité Universitätsmedizin"],"models":[],"people":["Sofia Järnum","Stef van Grieken","Adrian Schreiber","Philipp Enghard"]},"firstPublishedAt":"2026-10-01T11:41:02Z","updatedAt":"2026-10-01T11:41:02Z","sourceCount":1,"hasPrimarySource":false,"sources":[{"outlet":"Unite.AI","title":"Hansa Biopharma Deploys Cradle’s AI Platform Across Discovery Pipeline","url":"https://unite.ai/hansa-biopharma-deploys-cradles-ai-platform-across-discovery-pipeline","publishedAt":"2026-10-01T11:41:02Z","type":"press","primary":false,"lead":true}],"sourceNotes":null,"discussions":[],"thread":null,"cite":{"text":"Digest AI, \"Hansa Biopharma adopts Cradle’s AI platform for autoimmune disease drug discovery\", 1 October 2026, https://digestai.news/story/hansa-biopharma-adopts-cradles-ai-platform-for-autoimmune-disease-drug","publisher":"Digest AI","title":"Hansa Biopharma adopts Cradle’s AI platform for autoimmune disease drug discovery","datePublished":"2026-10-01T11:41:02Z","url":"https://digestai.news/story/hansa-biopharma-adopts-cradles-ai-platform-for-autoimmune-disease-drug"},"generatedBy":"Written by Digest AI's editorial model from the linked sources; the sources are the record.","license":"Headlines, digests and key points are written by Digest AI and may be quoted with a link to the story page. Linked articles belong to their publishers. Terms: https://digestai.news/terms#reuse"}